Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), announces it has entered into an option agreement to acquire Respira Therapeutics (Respira) and its lead product candidate, RT234, an investigational inhaled vardenafil dry‑powder therapy designed for as needed (PRN) use in pulmonary hypertension (PH), including PAH and PH‑ILD.
Read the full article: Gossamer Bio Enters into Option Agreement to Acquire Respira Therapeutics //
Source: https://www.businesswire.com/news/home/20250925334350/en/Gossamer-Bio-Enters-into-Option-Agreement-to-Acquire-Respira-Therapeutics-and-Its-Lead-Candidate-RT234-an-Inhaled-OnDemand-Vardenafil-for-Pulmonary-Hypertension